Vericel (VCEL) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Vericel (VCEL) Misses Q1 EPS by 6c
May 14, 2015 4:05 PM EDT
Total Revenues of $10.8 Million Reported for the First Quarter
Conference Call Today at 4:30pm Eastern Time
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the quarter ended March 31, 2015. Total revenues for the first quarter were generated primarily from net sales of Carticel® (autologous cultured chondrocytes) implants and surgical kits and Epicel® (cultured epidermal autografts), which were acquired on May 30, 2014 as part of the acquisition of... More
May 14, 2015 4:05 PM EDT
Total Revenues of $10.8 Million Reported for the First Quarter
Conference Call Today at 4:30pm Eastern Time
CAMBRIDGE, Mass., May 14, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today reported financial results for the quarter ended March 31, 2015. Total revenues for the first quarter were generated primarily from net sales of Carticel® (autologous cultured chondrocytes) implants and surgical kits and Epicel® (cultured epidermal autografts), which were acquired on May 30, 2014 as part of the acquisition of... More
